4D Molecular Therapeutics stock
FDMTNASDAQ4D Molecular Therapeutics, Inc., HealthcareISIN US35104E1001
48Score 48 out of 100, Weak
Price and trend
76 / 100
Price history
+10% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 9.5% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 28% below its 52-week high. Largest decline in 6 years: 95% (February 2021 to April 2025).
Chart figures for advanced users
- SMA 50$13.19
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.06
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.19
- The lowest closing price of the last twelve months.
- Resistance$16.76
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- 4D Molecular Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $851.35M, is number 200 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $85.21M (up 230,194.6% year on year) and a loss of $140.11M.
- MEQIRI Score 48 out of 100 (Weak): rank 401 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 44.3% a year since 2020, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $361.33M, financial debt $39.22M.Stability 68
Weaknesses
- DilutionShare count up 117% since 2020.Capital allocation 18
- Loss-makingLoss of $179.18M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$156.67M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 48.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has grown strongly since 2017, at around 40% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 91%, operating −187%, net −164%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 26 Feb 2027in 106 days
- Last reported
- 12 Nov 2026EPS reported −$1.08 (expected −$1.05)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$4.150.0%
- Revenue
- $13.26M0.0%
- Earnings per share
- −$4.090.0%
- Revenue
- $18.34M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $5.31M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Bizily ScottSale
16 Oct 2026, Chief Legal Officer
- Shares
- 1,635
- Price
- $12.84
- Value
- $20,993
- Kirn DavidSale
5 Oct 2026, See Remarks
- Shares
- 58,333
- Price
- $12.92
- Value
- $753,937
- Bizily ScottSale
16 Sept 2026, Chief Legal Officer
- Shares
- 1,635
- Price
- $13.65
- Value
- $22,318
Show 13 more
- Kirn DavidSale
14 Sept 2026, See Remarks
- Shares
- 58,333
- Price
- $13.90
- Value
- $811,004
- Bizily ScottSale
1 Sept 2026, Chief Legal Officer
- Shares
- 584
- Price
- $14.00
- Value
- $8,176
- Kirn DavidSale
19 Aug 2026, See Remarks
- Shares
- 69,076
- Price
- $15.75
- Value
- $1.09M
- Bizily ScottSale
17 Aug 2026, Chief Legal Officer
- Shares
- 1,635
- Price
- $12.20
- Value
- $19,947
- Bizily ScottSale
13 Aug 2026, Chief Legal Officer
- Shares
- 1,635
- Price
- $12.00
- Value
- $19,620
- Kirn DavidSale
4 Aug 2026, See Remarks
- Shares
- 26,842
- Price
- $10.23
- Value
- $274,596
- Kirn DavidSale
3 Aug 2026, See Remarks
- Shares
- 12,415
- Price
- $10.05
- Value
- $124,722
- Kirn DavidSale
10 Jul 2026, See Remarks
- Shares
- 15,725
- Price
- $12.03
- Value
- $189,233
- Kirn DavidSale
9 Jul 2026, See Remarks
- Shares
- 42,608
- Price
- $12.87
- Value
- $548,177
- Bizily ScottSale
30 Jun 2026, Chief Legal Officer
- Shares
- 6,566
- Price
- $14.00
- Value
- $91,924
- Bizily ScottSale
23 Jun 2026, Chief Legal Officer
- Shares
- 9,810
- Price
- $12.00
- Value
- $117,720
- Kirn DavidSale
22 Jun 2026, See Remarks
- Shares
- 114,746
- Price
- $10.47
- Value
- $1.2M
- Kirn DavidSale
1 Jun 2026, See Remarks
- Shares
- 1,922
- Price
- $10.02
- Value
- $19,258
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at 4D Molecular Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Pharming GroupPHARM.AS $933.24M49
- ORIC PharmaceuticalsORIC $932.87M32
- MeiraGTx HoldingsMGTX $929.7M61
- Aktis OncologyAKTS $915.84M37
- Syndax PharmaceuticalsSNDX $863.37M33
- AnnexonANNX $857.49M37
- AlumisALMS $856.86M38
- Rigel PharmaceuticalsRIGL $838.31M71
ETFs that hold 4D Molecular Therapeutics
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.04% | 0.35% | €1.21B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 11 Sep 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.